HPV Newsletters

Insight HPV for OB/GYNs - Fall 2005

Issue Date: October 31, 2005    Expires: October 31, 2008

In this issue of Insight HPV, we examine important prevention messages - from abstinence and education to the development of exciting new vaccines.

This program is designated for a maximum of 0.5 credits in category 1 of the Physician's Recognition Award of the American Medical Association.

Release Date: October 31, 2005
Expiration Date: October 31, 2008

Learning Objectives

After reading this publication, the participant should be able to:

• Identify the HPV types that cause most cases of genital warts and cervical cancer;
• Discuss with patient the roles of abstinence, "safer" sex, alcohol and drug use, education and vaccines in the prevention of HPV infection;
• Review key clinical data from monovalent, bivalent and quadrivalent vaccine trials;
• Evaluate the potential impact of an effective vaccination program for HPV.

Faculty

Jeffrey Lin, MD, FACOG

Associate Professor Director, Divisions of Gynecologic Oncology and General Obstetrics and Gynecology Chief, Gynecologic Surgery The George Washington University Medical Center Washington, DC
Disclosures: Dr. Lin has no potential conflicts of interest to disclose.

Henry Buck, MD

Head, Gynecology
Watkins Memorial Health Center
University of Kansas
Lawrence, KS
Disclosures: Dr. Buck has received grant/research support from Merck Research Laboratories and served as a consultant to 3M Pharmaceuticals and Merck & Co. Dr. Buck has participated in speakers' bureaus for 3M Pharmaceuticals, Digene, and TriPath, and has served on an advisory board for Merck & Co.

Stanley Gall, MD

Donald E. Baxter Professor and Chairman Emeritus Department of Obstetrics and Gynecology University of Louisville Health Sciences Center Louisville, KY
Disclosures: Dr. Gall has received grant/research support from and served as a consultant to Merck & Co., GlaxoSmithKline, and 3M Pharmaceuticals. Dr. Gall has participated in speakers' bureaus for Merck & Co., 3M Pharmaceuticals and Pfizer and has served on an advisory board for Merck & Co. and GlaxoSmithKline.

About this CME Activity

Please read the publication, reflection on its content, complete the CME Self-Assessment and CME Evaluation and return them to the address indicated. Upon receipt, your certificate of completion will be sent to you with the correct answers to the CME Self-Assessment. The estimated time a leaner will need to complete this self study activity is .5 hours.